Stockscreener 앱 받기
72.48
4.18%
-3.16
전일 마감가:
$75.64
열려 있는:
$75.9
하루 거래량:
1.02M
Relative Volume:
0.67
시가총액:
$5.82B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-12.20
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-6.51%
1개월 성능:
-3.90%
6개월 성능:
+50.56%
1년 성능:
+68.25%
1일 변동 폭
$72.41
$75.90
1주일 범위
$71.15
$80.18
52주 변동 폭
$35.95
$87.50
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
72.48 | 6.07B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
A Look At PTC Therapeutics (PTCT) Valuation As 2026 Revenue Guidance Reshapes Market Expectations - Sahm
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Utter, SVP at Ptc Therapeutics, sells $79k in shares By Investing.com - Investing.com Canada
Pauwels Eric, chief business officer of Ptc Therapeutics, sells $566k in shares - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares - MarketBeat
Eric Pauwels Sells 1,722 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7%Here's Why - MarketBeat
PTC Therapeutics reports $92.5M in Q4 Sephience revenue - Investing.com
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
PTC Therapeutics Reports Preliminary 2025 Product Revenue, Sets 2026 Product Revenue Guidance - marketscreener.com
Ptc Therapeutics provides update at J.P. Morgan annual healthcare conference - marketscreener.com
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - Yahoo Finance
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate - Chartmill
PTC Therapeutics, Inc. $PTCT Shares Purchased by SG Americas Securities LLC - MarketBeat
Market Outlook: Will PTC Therapeutics Inc stock sustain high P E ratios2025 EndofYear Setup & Expert Approved Trade Ideas - moha.gov.vn
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup - Chartmill
Is PTC Therapeutics Inc. stock a safe haven assetEarnings Risk Report & Growth Focused Stock Pick Reports - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) EVP Sells $49,742.16 in Stock - MarketBeat
Neil Gregory Almstead Sells 1,026 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 3,016 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,279 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells $95,650.75 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells 2,139 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,789 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 5,149 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 4,879 Shares of Stock - MarketBeat
Stop Loss: Is GDRX stock vulnerable to regulatory risksBuy Signal & Daily Momentum Trading Reports - moha.gov.vn
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
PTC Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
What dividend safety score for PTC Therapeutics Inc. stockQuarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating - marketscreener.com
PTC THERAPEUTICS, INC. (PTCT) - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
How Royalty Sale, Sephience Approval and CEO Share Sale At PTC Therapeutics (PTCT) Has Changed Its Investment Story - Sahm
PTC Therapeutics (NASDAQ:PTCT) VP Sells $171,196.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 734 Shares - MarketBeat
Glenn Md Phd Steele Jr Sells 12,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Inc (PTCT) - MSN
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
PTC 테라퓨틱스 주식 (PTCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 08 '26 |
Sale |
76.50 |
4,602 |
352,057 |
82,887 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 09 '26 |
Sale |
77.41 |
1,722 |
133,300 |
81,165 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 12 '26 |
Sale |
78.70 |
1,024 |
80,589 |
80,141 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Jan 08 '26 |
Sale |
76.45 |
2,514 |
192,195 |
394,453 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Jan 08 '26 |
Sale |
76.45 |
866 |
66,206 |
92,428 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 08 '26 |
Sale |
76.56 |
4,033 |
308,760 |
113,626 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 09 '26 |
Sale |
77.93 |
2,314 |
180,320 |
111,312 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 08 '26 |
Sale |
76.45 |
881 |
67,352 |
115,196 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 08 '26 |
Sale |
76.45 |
59 |
4,511 |
6,791 |
4.73%
0.92%
자본화:
|
볼륨(24시간):